Sharon Lynch, M.D., is the principal MS investigator for an average of 20 to 25 pharmaceutical industry-sponsored studies. The research includes phase I through phase IV trials. Phase I trials of investigational MS drugs are initial trials to assess the effectiveness, dosage and safety of the investigational product. Phase IV trials assess long-term safety after a new drug has been approved by the FDA and released to the market. The KU Center for MS Care primarily studies pharmacological treatments, but it also participates in a variety of studies of cognition and mood in MS.
Dr. Lynch is a co-investigator on a number of grant-funded studies through the National Institutes of Health and the National MS Society. Her frequent collaborators at the University of Kansas Medical Center are Steven LeVine, Ph.D., In-Young Choi, Ph.D., Phil Lee, Ph.D., Hannes Devos, Ph.D., and Abiodun Akinwuntan, Ph.D., as well as Jared Bruce, Ph.D., at University of Missouri - Kansas City.
Every disease study unlocks more clues about the mysteries of MS. When you join a study, you become a part of the effort to help maintain, improve or discover new treatment methods. Will you join us to help advance MS care and enhance the quality of life?
Research participation is always voluntary and is only presented to members if it fits our mission of optimizing the quality of life and has been reviewed by our medical director.
For information on participating in a clinical trial, please speak with a neurologist during your next visit.